Eisai and Biogen Report Positive Data for Subcutaneous Alzheimer's Drug

The findings, detailed during a session at the 2026 conference, indicate that a once-weekly 500 mg subcutaneous dose achieves drug exposure levels similar to the approved intravenous regimen of 10 mg/kg every two weeks. This bioequivalence, supported by an exposure ratio of 104%, suggests that the route of administration does not compromise the drug's ability to clear amyloid or slow cognitive decline. Researchers noted that clinical outcomes remained consistent across various body weight groups, reinforcing the viability of a fixed-dose subcutaneous approach.

Safety profiles for the autoinjector formulation also aligned with the existing intravenous treatment. Incidence rates of ARIA-E and immunogenicity remained low, with no neutralizing antibodies detected in the study group. Early real-world evidence from two U.S. treatment centers further supports these findings; patients transitioning to or initiating with the subcutaneous method reported high levels of satisfaction and convenience. If granted FDA approval, this delivery method would provide a flexible alternative for patients managing the long-term progression of Alzheimer’s.